Roche receives FDA 510(k) clearance for new cobas eplex respiratory pathogen panel 3
Roche announced the FDA 510(k) clearance of the cobas eplex respiratory pathogen panel 3 (RP3), a flexible syndromic test that detects up to 19 viral and bacterial targets from a single nasopharyngeal swab. The panel offers up to five customizable configurations, requires less than one minute of hands-on time, and delivers results in under two hours.
Primary source
Company press release (PR Newswire), November 2, 2026
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs
Machine-summarized from the source above; not independently reported. How we use automation